U.S. Markets closed

Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update

-- ZEMDRI (plazomicin), approved in the U.S. for the treatment of adults with complicated urinary tract infections --

-- Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first two weeks --

-- Conference call today at 4:30 p.m. Eastern Time --

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today reported financial results for the second quarter ended June 30, 2018, and provided an update on its commercial and corporate activities.

“With the launch of ZEMDRI, a much needed once-daily antibiotic, we are now able to offer healthcare practitioners a new treatment option for patients with certain serious bacterial infections,” said Blake Wise, Achaogen’s Chief Executive Officer. “We are excited about ZEMDRI’s potential to help patients, and we are pleased with the early interest we are seeing from the infectious disease community.”

Recent Highlights and Upcoming Milestones

  • ZEMDRI Launch: On July 20, 2018, ZEMDRI was made available for use in the United States. Achaogen has deployed a team of experienced sales and medical professionals to communicate the proper use, efficacy and safety of ZEMDRI, including its once-daily, 30-minute dosing regimen. Greater than 75% of high priority accounts have been engaged in the first two weeks.
  • ZEMDRI U.S. Approval: On June 25, 2018, the U.S. Food and Drug Administration (FDA) approved ZEMDRI (plazomicin) for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.
  • ZEMDRI New Technology Add-On Payment (NTAP) Approval: On August 2, 2018, ZEMDRI received approval from Centers for Medicare & Medicaid Services (CMS) for NTAP, a special designation for new technologies that demonstrate substantial clinical improvement over current treatments. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care Diagnostic Related Group (DRG) reimbursement, of up to 50% of the cost of ZEMDRI for a period of two to three years, starting on October 1, 2018.
  • European Marketing Authorization Application (MAA): Achaogen plans to submit a MAA to the European Medicines Agency for plazomicin in the second half of 2018.

Other Corporate Milestones

  • Strategic Update: On July 26, 2018, the Company announced a strategic update and corporate restructuring to improve its cost structure for long-term success; a one-time restructuring charge of approximately $6.0 million is expected in the second half of 2018.

Second Quarter 2018 Financial Results

Cash Position: At June 30, 2018, Achaogen had $100.5 million in unrestricted cash, cash equivalents and short-term investments compared to $164.8 million at December 31, 2017.

Revenue: Contract revenue totaled $2.6 million for the second quarter of 2018 compared to $1.3 million for the same period in 2017. The increase in contract revenue during the second quarter was primarily related to Biomedical Advanced Research and Development Authority (BARDA) C-Scape contract revenues. As of June 30, 2018, $8.4 million remains under the BARDA C-Scape contract and up to an additional $6.0 million may be available under BARDA contract options. All Achaogen revenue consisted of U.S. government and Gates Foundation funding for the research and development of product candidates.

Research and Development (R&D): R&D expenses in the second quarter of 2018 were $36.9 million, compared to $22.2 million reported for the same period in 2017. The increase in R&D expenses during the quarter was primarily due to a $7.5 million milestone license fee associated with FDA approval of ZEMDRI, increases in R&D headcount, facility expenses, external expenses related to manufacturing ZEMDRI, and external expenses related to C-Scape and early research programs.

General and Administrative (G&A): G&A expenses in the second quarter of 2018 were $20.5 million, compared to $8.9 million for the same period in 2017. The increase in G&A expenses during the quarter was primarily due to increases in G&A headcount, including the field sales team, facility expenses and expenses related to the pre-commercialization of ZEMDRI.

Change in warrant and derivative liabilities for the second quarter of 2018 was a $4.6 million gain compared to a $4.2 million gain for the same period in 2017. The increase was primarily due to the change in the estimated fair value of the warrant liability which is mainly driven by the change in the Company’s stock price.

Net Loss: Achaogen reported a net loss of $50.0 million for the second quarter of 2018, compared to a net loss of $26.1 million for the same period in 2017. Diluted net loss was $1.20 per share for the second quarter of 2018, compared to diluted net loss of $0.78 per share for the same period in 2017. As of June 30, 2018, there were approximately 45.0 million shares of common stock outstanding.

Conference Call
The Company will host a conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. To participate by telephone, please dial 888.254.3590 (Domestic) or 323.994.2093 (International). The conference ID number is 2893252. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.achaogen.com. The archived audio webcast will remain available on the Company's website for 30 days following the conference call.

About Achaogen
Achaogen is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen's first commercial product is ZEMDRI, for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis. The Achaogen ZEMDRI program was funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. The Company is currently developing C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, which is also supported by BARDA. Achaogen is also developing a new aminoglycoside program, which is supported by CARB-X. All product candidates are investigational, have not been determined to be safe or efficacious, and have not been approved for commercialization. For more information, visit the Achaogen website at www.achaogen.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential uses and advantages of ZEMDRI, Achaogen commercial objectives and the Achaogen pipeline of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Achaogen's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the regulatory approval process; market size and growth; timing of activities, including launch dates of products; statements about the efficacy, safety and tolerability of ZEMDRI and product candidates; the risks and uncertainties of product sales; the risk of when bacteria will evolve resistance to ZEMDRI and product candidates; Achaogen's reliance on third-party contract manufacturing organizations for manufacture and supply, including sources of certain raw materials; risk of third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Achaogen business in general, see Achaogen current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018, and its Quarterly Report on Form 10-Q filed on or about August 6, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances, or otherwise.

Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
arr@lifesciadvisors.com

Media Contact:
Denise T. Powell
Red House Consulting, LLC
dpowell@achaogen.com

Source: Achaogen, Inc.

© 2018 Achaogen, Inc. All Rights Reserved.

 
Achaogen, Inc.
Condensed Consolidated Statements of Operations
(in thousands except share and per share data)
(unaudited)
               
  Three Months Ended   Six Months Ended
  June 30,   June 30,
    2018       2017       2018       2017  
Contract revenue $ 2,562     $ 1,266     $ 4,705     $ 8,729  
Operating expenses            
Research and development   36,930       22,199       67,840       40,797  
General and administrative   20,478       8,860       35,547       15,609  
Total operating expenses   57,408       31,059       103,387       56,406  
Loss from operations   (54,846 )     (29,793 )     (98,682 )     (47,677 )
Interest expense   (295 )     (723 )     (900 )     (1,430 )
Change in warrant and derivative liabilities   4,576       4,225       2,045       (10,731 )
Loss on debt extinguishment               (819 )      
Other income, net   596       221       1,158       510  
Net loss $ (49,969 )   $ (26,070 )   $ (97,198 )   $ (59,328 )
Net loss per common share            
Basic $ (1.11 )   $ (0.68 )   $ (2.18 )   $ (1.61 )
Diluted $ (1.20 )   $ (0.78 )   $ (2.19 )   $ (1.61 )
Weighted-average shares used to calculate net loss per common share              
Basic   44,865,861       38,072,763       44,612,623       36,905,802  
Diluted   45,691,646       39,092,279       45,425,617       36,905,802  
                               


 
Achaogen, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
    June 30, 2018   December 31,
2017
    (unaudited)    
Assets        
Current assets:        
Cash and cash equivalents   $ 63,291   $ 145,219
Short-term investments     37,244     19,572
Contracts receivable     1,458     1,357
Prepaids and other current assets     9,056     6,367
Restricted cash     5,757     5,891
Total current assets     116,806     178,406
Property and equipment, net     20,611     14,810
Restricted cash     1,206     3,855
Other long-term assets     4,074    
Total assets   $ 142,697   $ 197,071
Liabilities, contingently redeemable common stock and stockholders’ equity        
Current liabilities:        
Accounts payable   $ 6,578   $ 6,862
Accrued liabilities     23,508     15,441
Loan payable, current portion         12,500
Deferred revenue     696     2,100
Total current liabilities     30,782     36,903
Loan payable, long-term     24,622     9,457
Warrant liability     7,477     9,774
Derivative liability     938     686
Deferred rent     9,962     8,289
Total liabilities     73,781     65,109
Contingently redeemable common stock     10,000     10,000
Stockholders’ equity     58,916     121,962
Total liabilities, contingently redeemable common stock and stockholders’ equity   $ 142,697   $ 197,071
             

  • Allergan (AGN) Q3 Earnings Preview: What's in the Cards?
    Business
    Zacks

    Allergan (AGN) Q3 Earnings Preview: What's in the Cards?

    Allergan (AGN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 30, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Why DISH Network, 3M, and Compass Minerals International Slumped Today
    Business
    Motley Fool

    Why DISH Network, 3M, and Compass Minerals International Slumped Today

    Tuesday was not a good day on Wall Street, as markets reacted negatively to a range of factors including global macroeconomic fears of a slowdown in China and their potential impact on earnings of big multinational corporations. DISH Network (NASDAQ: DISH), 3M (NYSE: MMM), and Compass Minerals International (NYSE: CMP) were among the worst performers on the day. Shares of DISH Network dropped 8% after the satellite television provider suffered a downgrade from an investment analyst company.

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Business
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill
    Finance
    Fortune

    Mega Millions $1.6 Billion Jackpot Also Comes With a Mega Millions Tax Bill

    With a jackpot of $1.6 billion, tonight’s Mega Millions lottery drawing is the biggest in history. The Mega Millions drawing will be held Tuesday night at 11 p.m. ET—and the odds are categorically against you. The Mega Millions tax bite, though, is pretty solid.

  • Tesla Skeptic Andrew Left Is Now Long on ‘Proven Hit’ Model 3
    Business
    Bloomberg

    Tesla Skeptic Andrew Left Is Now Long on ‘Proven Hit’ Model 3

    Citron Research’s Andrew Left, a vocal and long-term Tesla short, said in a report Tuesday that the electric-car maker is snatching customers from BMW, Mercedes, Toyota and Honda. In a Bloomberg Television interview, he said Chief Executive Officer Elon Musk has distracted investors from a company that’s turning a corner. “Elon Musk has made such a sideshow of himself that people started to forget about -- including myself -- the underlying business,” Left said on Bloomberg TV.

  • Suze Orman missed the point of retirement, and that’s why she went back to work
    News
    MarketWatch

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • MARKETS: Here's why stocks are selling off right now and what a bottom would look like
    Business
    Yahoo Finance Video

    MARKETS: Here's why stocks are selling off right now and what a bottom would look like

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Business
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • Apple plans to launch streaming service globally early next year
    Finance
    American City Business Journals

    Apple plans to launch streaming service globally early next year

    Apple Inc. may be late to the streaming game, but when the computer giant does launch its video platform, it plans to take it global. The company aims to launch its streaming service in more than 100 countries, reported The Information. Apple (NASDAQ: AAPL) plans to launch its streaming service in the United States in the first half of next year, sources told the tech news site, and expand it internationally in the following months.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back following its sharp sell-off at the beginning of October, but Morgan Stanley says the selling is going to pick back up soon. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Saudi Arabia conference site hacked with disturbing image of murdered journalist Jamal Khashoggi
    World
    The Independent

    Saudi Arabia conference site hacked with disturbing image of murdered journalist Jamal Khashoggi

    Hackers have hijacked the website of a major conference in Saudi Arabia and placed an image of the murdered journalist Jamal Khashoggi on its homepage. The conference, dubbed “Davos in the Desert”, is due to take place this week in Riyadh but has been overshadowed by the withdrawal of several high-profile attendees over the murder of the Saudi dissident. The second annual Future Investment Initiative conference has billed itself as “a blueprint for the 22nd century” that is bringing together “the world’s most visionary and influential leaders in business, government and civil society”.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • Business
    Benzinga

    Morgan Stanley: 6 Ways Caesars Entertainment Can Create Value

    Gaming operator Caesars Entertainment Corporation (NASDAQ: CZR) boasts multiple upside catalysts that imply the stock is undervalued, according to Morgan Stanley. The Analyst Morgan Stanley's Thomas Allen initiated coverage of Caesars Entertainment 

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Trump’s Tax Push to Help Middle Class Could Help Top Earners Too
    Politics
    Bloomberg

    Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to $82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

  • Business
    Benzinga

    Upcoming Earnings: Tech Giant Microsoft To Report Tomorrow

    While several of MSFT’s divisions have reportedly been growing at a double-digit pace, the company’s cloud services divisions have been the major driver of revenue growth. Azure, the company’s cloud computing platform, grew 89 percent year over year, the fastest out of all of its products and services. Beyond the company’s cloud division, there are quite a few other areas that analysts have been focused on: LinkedIn, gaming and the Surface.

  • What the Market Missed in Kinder Morgan Inc.'s Results
    Business
    Motley Fool

    What the Market Missed in Kinder Morgan Inc.'s Results

    Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

  • Texas Instruments Earnings Are Next Test for Tumbling Semis
    Business
    Bloomberg

    Texas Instruments Earnings Are Next Test for Tumbling Semis

    (Bloomberg) -- With semiconductor stocks in retreat, Texas Instruments Inc.’s earnings report on Tuesday will be among the most closely watched for clues about demand for chips used across a broad spectrum of products.The world’s largest maker of analog

  • Business
    Reuters

    Caterpillar tries to allay earnings concerns after shares tank

    Caterpillar Inc (CAT.N) tried on Tuesday to ease mounting concerns about China and global demand after it affirmed its 2018 profit estimate, a move that investors feared signalled a cap in earnings growth and sparked a sell-off in its shares. The Deerfield, Illinois-based company has boosted the full-year profit outlook twice in the first two quarters of this year. The move came days after China reported the weakest economic growth since the global financial crisis, and the International Monetary Fund cut the global growth outlook for 2018 and 2019.

  • S&P 500 closes down for fifth day as stocks retreat in wake of China selloff
    News
    MarketWatch

    S&P 500 closes down for fifth day as stocks retreat in wake of China selloff

    U.S. stocks bounced off intraday lows and major indexes trimmed early losses Tuesday, but the S&P 500 still finished lower for a fifth session as a big drop in the Chinese market revived fresh questions about the global economy. The Dow Jones Industrial Average (DJIA) fell 125.98, or 0.5%, to 25,191.43 after being down more than 500 points earlier. (DJIA)On Monday, Dow industrials and the S&P 500 closed lower while the Nasdaq bucked the trend to edge higher.

  • What Energy Transfer’s Technical Indicators Suggest
    Finance
    Market Realist

    What Energy Transfer’s Technical Indicators Suggest

    How Energy Transfer Stock Has Fared (Continued from Prior Part) Moving averages Let’s see where Energy Transfer (ET) stock might go from here. Energy Transfer stock is currently trading at $16.47, almost 6% and 3% below its 50-day and 200-day moving